Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting.

IF 3.3 3区医学 Q2 PHARMACOLOGY & PHARMACY

Therapeutic Advances in Chronic Disease Pub Date : 2023-12-04 eCollection Date: 2023-01-01 DOI:10.1177/20406223231215701

Shenhe Jin, Yi Liu, Ye Zhang, Fengping Zhou, Liangshun You, Jin Zhang

引用次数: 0

Abstract

BiTE, has recently been approved in Europe for relapsed or refractory follicular lymphoma (R/R FL) treatment in adults who have received at least two prior systemic therapies. In a pivotal phase II study, 4 49 of 90 (54%) enrolled patients achieved CR at the end of treatment, with a 24-month PFS of 77%.

查看原文本刊更多论文

靶向CD20/CD3的b细胞淋巴瘤双特异性T细胞接合物:2023 EHA年会上的最新进展

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Chronic Disease Medicine-Medicine (miscellaneous)

CiteScore

6.20

自引率

0.00%

发文量

108

审稿时长

12 weeks

期刊介绍： Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area.